#102 - Michael Osterholm, Ph.D.: COVID-19—Lessons learned, challenges ahead, and reasons for optimism and concern

Mar 31, 2020 Episode Page ↗
Overview

Dr. Michael Osterholm, Director of the Center for Infectious Disease Research and Policy, discusses COVID-19's spread, immunity, case fatality rates, and the critical challenges of supply chains for PPE, drugs, and testing. He emphasizes the long-term nature of the pandemic and the need to protect healthcare workers.

At a Glance
24 Insights
1h 22m Duration
17 Topics
5 Concepts

Deep Dive Analysis

Initial Outlook on COVID-19 Pandemic

Early Understanding of Virus Transmission and Spread

Seasonality and Long-Term Trajectory of the Virus

Evidence for Durable Immunity Against Reinfection

Challenges in Determining True Case Fatality Rate

Impact of Comorbidities on Disease Severity and Mortality

Conditions for Limiting US COVID-19 Deaths

Critical Supply Chain Issues for Healthcare

Protecting Healthcare Workers Amidst PPE Shortages

Implosion of COVID-19 Testing Capabilities

Vaccine Development Challenges and Timeline

Antiviral Drug Development and Repurposed Treatments

Long-Term Health Outcomes for COVID-19 Survivors

Understanding R0 and Pre-symptomatic Transmission

Difficulties in Forecasting Pandemic Progression

Global Response and Country-Specific Outcomes

Parting Message on Navigating the Pandemic

R-naught (R0)

R0 is the average number of people an infected individual transmits a disease to. For COVID-19, it was initially estimated between 2 and 2.4, but this number is complicated by super-spreaders and interventions.

Antibody-Dependent Enhancement (ADE)

ADE is a phenomenon where the presence of a small amount of antibody can worsen a subsequent infection, leading to a shock-like picture. This was a safety concern in SARS vaccine development and is a potential challenge for COVID-19 vaccines.

Pre-symptomatic Transmission

This refers to individuals who are infected and infectious before they show any discernible clinical symptoms. High viral loads can be present in the throat during this period, contributing to efficient spread through breathing and talking.

Aerosol Transmission

Aerosols are small particles, smaller than five nanometers, that can be produced by talking and breathing, not just coughing or sneezing. They can travel further than droplets and contribute to virus spread, making N95 respirators crucial for protection.

Syndromic Surveillance

A public health method that monitors the occurrence of specific constellations of signs and symptoms (e.g., influenza-like illness) in a community. This allows for early detection of outbreaks when specific diagnostic testing is limited.

?
What is the current outlook on the COVID-19 pandemic?

The virus is expected to continue transmitting until 50-70% of the population is infected and immune, potentially over many months, with no easy way out between suppressing the economy and overwhelming healthcare systems.

?
Is there durable immunity after COVID-19 infection?

A study in macaque monkeys showed protection against re-challenge a month after recovery, suggesting durable short-term immunity, which bodes well for long-term immunity.

?
What is the true case fatality rate (CFR) of COVID-19?

The true CFR is difficult to ascertain due to missed cases and deaths, but it's estimated to be in the 1-2.5% range, heavily influenced by age and underlying health conditions like obesity.

?
What conditions would need to be true for fewer than 100,000 Americans to die from COVID-19?

Achieving this would require an unsustainable Wuhan-like suppression of transmission and preventing the collapse of the healthcare system, which is currently facing severe shortages of critical supplies and personnel.

?
How well are healthcare workers protected from COVID-19?

Healthcare workers face significant risks due to severe shortages of N95 respirators, which are essential for protection against aerosol transmission, leading to many exposures and infections.

?
What is the status of COVID-19 testing in the US?

Despite increased demand, the US is facing an impending 'implosion' of testing capabilities due to severe global shortages of reagents needed for PCR and other tests, limiting who can be tested.

?
When can we expect a COVID-19 vaccine?

A vaccine is unlikely sooner than 18 months due to significant safety concerns like Antibody-Dependent Enhancement (ADE) and the lack of existing large-scale manufacturing capacity for rapid production.

?
What is the outlook for effective antiviral treatments for COVID-19?

Developing effective antivirals is historically challenging, and while many repurposed drugs are being explored, rigorous randomized controlled trials are needed to determine their true efficacy and safety.

?
What are the long-term health consequences for COVID-19 survivors?

The long-term health of survivors is largely unknown, but there are concerns about lingering issues like myocarditis, kidney disease, and lung fibrosis, though MERS survivors have not shown reinfection.

?
How does COVID-19 transmission in children compare to influenza?

Unlike influenza, where sick children are significant transmitters, children with COVID-19 appear to get infected at the same rate as adults but often show no clinical signs or symptoms.

1. Remember the Human Cost

Despite the use of statistics and numbers, always remember that the pandemic’s impact is deeply personal, affecting loved ones and leading to serious illness or death for many.

2. Focus on Effective Solutions

Maintain hope that the crisis will be overcome, but critically focus on identifying and implementing the most effective approaches to navigate the challenges.

3. Seek In-Depth Information

Avoid relying on soundbites or short segments for complex topics like pandemics, as they fail to convey the necessary complexities and long-term views. Instead, seek venues that provide detailed, comprehensive discussions.

4. Understand Aerosol Transmission

Recognize that viruses can transmit via aerosols, which are small particles produced within the typical six-foot droplet zone, meaning protection beyond just droplet precautions is necessary.

5. Anticipate Future Challenges

Shift from a reactive ‘playing checkers’ approach to a proactive ‘playing chess’ strategy by anticipating where the pandemic is headed, rather than just reacting to its current state, to stay ahead of its rapid progression.

6. Interpret Models with Caution

Understand that all models are inherently wrong to some degree; while they can provide helpful information, their wide variability and potential for error mean their projections should be interpreted with significant caution.

7. Challenge Assumptions with ‘What You Have to Believe’

When analyzing complex situations, use the ‘What You Have to Believe’ game to probe the limits of current understanding by considering extreme scenarios and identifying the necessary conditions for them to be true.

8. View Crisis as a Long-Term Movie

Understand that the current situation is merely a snapshot, not the full movie; anticipate that the pandemic will unfold over years, revealing more similarities in outcomes across regions when viewed over the long term.

9. Adapt to Available Resources

When facing a crisis, understand that you must operate with the resources currently available, not with what you ideally wish for, and adapt strategies accordingly.

10. Assume COVID-19 for Flu-like Illness

If a patient presents with an influenza-like illness during the pandemic, assume they are COVID-19 infected, especially if influenza circulation is low, and proceed with appropriate isolation and care.

11. Prioritize COVID-19 Testing

In situations of reagent scarcity, prioritize COVID-19 testing for hospitalized sick individuals, symptomatic healthcare workers, and long-term care facility workers to manage the outbreak effectively.

12. Prioritize Healthcare Worker Serology

Implement widespread serology testing for healthcare workers to identify those with likely immunity, allowing them to safely return to work and be deployed to high-risk areas without fear of reinfection or infecting others.

13. Support Healthcare Worker Mental Health

Recognize and address the severe mental health toll on healthcare workers, providing support and care to help them cope with battlefield-like trauma during prolonged crisis periods.

14. Address All Crisis Fronts Simultaneously

Recognize that the crisis presents problems on multiple fronts (drugs, personnel, equipment), and an ‘all hands on deck’ approach is required for all of them, as bottlenecks will vary by location.

15. Strategically Relocate Healthcare Workers

Consider relocating healthcare workers to cities identified as current or imminent epicenters of the outbreak to address critical bottlenecks, provided they can be adequately protected with necessary PPE.

16. Demand Honesty and Accountability

Acknowledge the collective responsibility for being ill-prepared for the pandemic and demand honesty about the current situation and future challenges.

17. Utilize Syndromic Surveillance

Revert to syndromic surveillance methods, like monitoring influenza-like illness trends in physician offices, to detect community spread and determine when to implement aggressive public health measures, especially when testing reagents are limited.

18. Exercise Caution with Unproven Treatments

Be cautious about using unproven treatments, as some drugs, like chloroquine, may act as immunologic modulators and could potentially worsen certain conditions, highlighting the need for robust data.

19. Prioritize Rigorous Treatment Data

Support the rapid establishment of systems to collect meaningful data on potential therapies through randomized controlled trials, maintaining an open mind and letting the data guide conclusions on efficacy and safety.

20. Research Long-Term Survivor Health

Prioritize research into the long-term health outcomes of COVID-19 survivors to understand potential lingering issues like myocarditis, kidney disease, or lung fibrosis.

21. Investigate Comorbidity Mechanisms

Research the specific mechanisms by which underlying comorbidities, such as type 1 diabetes or obesity, predispose individuals to severe COVID-19 outcomes.

22. Identify Super Spreader Characteristics

Investigate the characteristics of individuals who become ‘super spreaders’ to better identify them a priori and implement more effective isolation strategies.

23. Improve Predictive Intelligence

Develop better predictive intelligence to anticipate future outbreak fronts and resource needs, addressing the current shortcoming in proactive planning and response.

24. Establish Global Resource Coordination

Advocate for global leadership and coordination to equitably allocate critical resources like tests and N95 masks, preventing a ‘haves and have-nots’ scenario where countries compete for essential tools.

If you don't know where you're going, any road will get you there.

Michael Osterholm

I have every reason to believe that it won't stop transmitting in any meaningful way until we get 50 or 60 or 70 percent of the population infected.

Michael Osterholm

I've come to the point in my old age that when something walks like a duck, looks like a duck, and quacks like a duck, I think it's probably a duck.

Michael Osterholm

When you go to war, you can't go to war with what you want. You have to go to war with what you have.

Michael Osterholm

Trying to stop this kind of transmission is like trying to stop the wind.

Michael Osterholm
20%
Estimated percentage of global influenza pandemics that started in winter Based on the last 10 influenza pandemics over 250 years.
30%
Estimated percentage of global influenza pandemics that started in spring Based on the last 10 influenza pandemics over 250 years.
20%
Estimated percentage of global influenza pandemics that started in summer Based on the last 10 influenza pandemics over 250 years.
30%
Estimated percentage of global influenza pandemics that started in fall Based on the last 10 influenza pandemics over 250 years.
50-70%
Projected percentage of US population that needs to be infected to achieve herd immunity Michael Osterholm's estimate for meaningful cessation of transmission.
70%
Percentage of men over 65 who smoke in China Compared to less than 2% of women in the same age group, impacting COVID-19 outcomes.
45%
Percentage of US population over age 50 considered moderate to severely obese A significant risk factor for severe COVID-19 illness and death.
700,000
Number of Americans living with end-stage renal disease Renal disease is a comorbidity associated with bad outcomes for COVID-19.
8%
Case fatality rate (CFR) in Italy for cases over age 80 with underlying health problems Reflects the impact of age and comorbidities on mortality.
Over 900
Number of police officers infected in New York City As of March 30th, with 13% of the workforce out and three deaths.
150
Daily deaths in New York City from COVID-19 Compared to an average of 100 deaths per day from all causes in the past.
35 million
Monthly production capacity of N95 respirators by 3M in the US The largest US manufacturer, trying to increase by 5-7%.
2 million
N95 respirators used by one hospital in New York in one month Illustrates the immense demand for PPE.
35 million
N95 respirators in the US Strategic National Stockpile A limited supply compared to estimated needs.
400 million or more
Estimated N95 respirators needed for the first couple of months Highlighting the severe shortfall.
85%
Percentage of key antibiotics made outside the United States Many are made in China and the Lombardi region of Italy, creating severe supply chain vulnerability.
5,000
Number of antiviral inhibitors proposed in scientific literature (1963-present) Only 90 were approved for final use, with about 40 for HIV.
45 out of 60
Number of choir members in Seattle who tested positive for COVID-19 Following a single practice, illustrating a super-spreader event.
1,000 times higher
Viral load in throats of early COVID-19 patients compared to SARS Observed at the very first moments of clinical symptoms, on culture data.